A Three-Component Solvent for the Treatment for COVID-19: Is the Data in Place for Clinical Trial?

This letter outlines the potential use of a three-component solvent, with strong anti-viral properties, as an economical and efficient treatment of COVID-19. It focuses on the generation and delivery of the alcohol-based solvent as nanodroplets deep within a patients lungs to reduce the viral load and potentially reduce the impact of a bradykinin or cytokine storm. The treatment is considered for compassionate use where other methods are not available or will not work.

Content

Author and article information

Journal

Title: UnisaRxiv

Publisher: UNISA Press

Publication date (Electronic preprint): 26 January 2021

Affiliations

[1 ] Valdosta State University, USA

[2 ] Forrest General Hospital and Hattiesburg Clinic, USA

Author information

Thomas Manning https://orcid.org/0000-0002-0862-1739

Jenu Thomas-Richardson https://orcid.org/0000-0001-8431-8865

Steven Stogner https://orcid.org/0000-0002-8154-5584

Article

DOI: 10.25159/UnisaRxiv/000003.v1

SO-VID: dee890fe-6667-4a1e-aedf-8f83464e568b

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

History

Date received : 26 January 2021

Date accepted : 22 February 2021

Data availability: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

ScienceOpen disciplines: Medicine

Keywords: COVID-19,treatment,protein,ethanol,alcohol